Prognostic evaluation with focus on renal function of molecular target drugs for Unresectable or Metastatic Renal Cell Carcinoma patients with Renal Dysfunction
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
Most Recent Events
- 20 Oct 2017 Status changed from recruiting to discontinued.
- 17 May 2016 New trial record